Specific inhibitors of inducible nitric oxide synthase: efficacy in a rodent model of sepsis.
Fretland
D J
DJ
Searle Research and Development, Skokie, IL 60077, USA. donald.j.fretland@monsanto.com
Widomski
D L
DL
Anglin
C P
CP
Moore
W
W
Jerome
G
G
Kornmeier
C
C
Connor
J
J
Branson
L
L
Wyatt
P
P
Manning
P
P
Toth
M
M
Webber
R K
RK
Hansen
D
D
Hallinan
E A
EA
Hagen
T
T
Bergmanis
A
A
Pitzele
B
B
Currie
M G
MG
D000818:Animals; D002460:Cell Line; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008070:Lipopolysaccharides / Q000633:toxicity; D051379:Mice; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D052247:Nitric Oxide Synthase Type II; D009573:Nitrites / Q000652:urine; D018805:Sepsis / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D004791:Enzyme Inhibitors; D008070:Lipopolysaccharides; D009573:Nitrites; D014409:Tumor Necrosis Factor-alpha; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse